Adlai Nortye
Update in progressANL (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Adlai Nortye Ltd. is a clinical-stage company that develops pharmaceutical products through its subsidiaries. Its pipeline includes AN0025, a small-molecule EP4 antagonist in phase Ib for rectal and esophageal cancer, with phase II in high-risk rectal cancer; AN9025, a pan-RAS(ON) inhibitor in phase 1a; AN4035, a CEACAM5-targeting ADC; AN8025, a trispecific antibody fusion in phase Ia; and AN4005, a PD-L1 inhibitor in phase 1b. It also offers tech transfer and consulting. Founded 2004, North Brunswick, NJ.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- -0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationSingapore
- CEOMr. Yang Lu EMBA
- Founded2004
- Employees109
- Websitewww.adlainortye.com
Identifiers
- ISINUS00704R1095
- FIGIBBG01HP11SV4
- CIK0001944552